Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System… | Phase 2 | terminated | Oct 31, 2013 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating…(NYSCT MM) | Phase 1 | withdrawn | Apr 24, 2018 | Jonsson Comprehensive Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes… | Phase 2 | withdrawn | Jun 19, 2020 | National Cancer Institute (NCI) | zero accrual | Enrollment / accrual |
| NCT03145870 | Prevalence of Asymptomatic Thrombosis in Multiple Myeloma | N/A | withdrawn | May 9, 2017 | Centre Hospitalier Universitaire, Amiens | investigator choice | Investigator |
| NCT03983486 | Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple…(CIF-PM) | — | withdrawn | Jun 12, 2019 | Centre Hospitalier Universitaire, Amiens | technical problem | Other (stated, no rule matched) |
| NCT02547948 | CD19-targeting CAR T Cells for B Cell Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 14, 2015 | Fuda Cancer Hospital, Guangzhou | not stated | Not stated |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With… | Phase 1 / Phase 2 | terminated | Apr 16, 2013 | Amgen | Enrollment halted during phase 2 to reformulate the investigational product | Enrollment / accrual |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post-… | Phase 2 | withdrawn | Dec 28, 2016 | University of Arkansas | Withdrawal of study support | Other (stated, no rule matched) |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | Phase 2 | withdrawn | Aug 6, 2018 | University of Michigan Rogel Cancer Center | Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to… | COVID-19 / pandemic |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | Phase 1 / Phase 2 | terminated | Sep 29, 2009 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Oct 29, 2009 | Mayo Clinic | Lack of funding | Funding |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | Ajai Chari | Low enrollment | Enrollment / accrual |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | Phase 2 | withdrawn | Oct 25, 2018 | Brown University | lack of funding | Funding |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating… | Phase 1 | terminated | Mar 12, 2009 | Fred Hutchinson Cancer Center | Terminated due to lack of funding | Funding |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk… | Phase 2 | terminated | May 14, 2009 | M.D. Anderson Cancer Center | Study was closed early due to toxicity | Safety / toxicity |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Aug 30, 2017 | Cogent Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent…(A+B) | Phase 3 | terminated | Mar 1, 2010 | Novartis Pharmaceuticals | The study was terminated early as it did not meet the Primary efficacy objective after primary… | Efficacy / futility |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From…(DARALLO) | Phase 2 | withdrawn | Jul 18, 2019 | Assistance Publique - Hôpitaux de Paris | Promotor decision | Other (stated, no rule matched) |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in… | Phase 1 / Phase 2 | terminated | Apr 29, 2016 | BioInvent International AB | Full clinical hold from FDA | Other (stated, no rule matched) |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic… | Phase 1 | terminated | May 27, 2016 | Yale University | Based on FDA requirements | Other (stated, no rule matched) |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 7, 2016 | Bayer | Due to the changes of standard of care and the slow recruitment of participants. | Enrollment / accrual |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory… | Phase 2 | terminated | Sep 21, 2011 | NYU Langone Health | PI left institution. | Investigator |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | Phase 1 / Phase 2 | terminated | Jun 27, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | Phase 2 | withdrawn | Nov 1, 2017 | Ohio State University Comprehensive Cancer Center | Sponsor decision | Sponsor / business decision |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT03173430 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell… | Early Phase 1 | terminated | Jun 1, 2017 | Abramson Cancer Center at Penn Medicine | PI decided to close study due to slow accrual. | Enrollment / accrual |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple…(SMR-3184) | Phase 1 / Phase 2 | terminated | Jun 23, 2017 | Allarity Therapeutics | The study was terminated early due to sponsors decision | Other (stated, no rule matched) |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy,… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2018 | M.D. Anderson Cancer Center | Lack of Funding | Funding |
| NCT04243109 | Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients…(POCODEX) | Phase 2 | terminated | Jan 28, 2020 | Maimónides Biomedical Research Institute of Córdoba | Low recruitment rate. Lack of interest of the sponsor. | Enrollment / accrual |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | May 12, 2009 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of continuing review | Other (stated, no rule matched) |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in…(Velcadito) | Phase 4 | terminated | May 16, 2016 | Basque Health Service | Low recruiment. | Other (stated, no rule matched) |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia… | Phase 2 | terminated | Aug 31, 2017 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive…(IDEALL) | Phase 2 | withdrawn | Aug 1, 2018 | Takeda | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT03670888 | A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20… | Phase 1 | terminated | Sep 14, 2018 | JHL Biotech, Inc. | The development was stopped due to company's strategy consideration | Sponsor / business decision |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With… | Phase 3 | terminated | Sep 14, 2018 | JHL Biotech, Inc. | The development was stopped due to company's strategy consideration | Sponsor / business decision |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or… | Phase 1 / Phase 2 | terminated | Sep 23, 2015 | Innate Pharma | Sponsor decision | Sponsor / business decision |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01571726 | Imaging Studies and the Development of Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 14, 2020source: clinicaltrials